Synthorx, Inc.

Synthorx, Inc. is a biotechnology company focused on developing innovative therapies through the creation of a unique amino acid. Their groundbreaking technology aims to enhance medical treatments across various disease areas. Founded in 2014 and headquartered in the United States, Synthorx, Inc.

specializes in therapeutic solutions utilizing a proprietary amino acid technology. The company underwent an IPO on December 6, 2018, raising USD 131 mn, which was the total amount raised to date. The founder's history is not available, and there are no mentions of changes in business operations or any parent or subsidiary companies. Synthorx, Inc.

offers innovative biopharmaceutical therapies designed to improve treatment outcomes in various diseases. Their products leverage a distinct amino acid that allows for enhanced therapeutic effects, aiming to address unmet medical needs. The company targets a global clientele, focusing on key markets in North America, Europe, and parts of Asia to ensure a broad reach of their solutions. For the most recent year, Synthorx, Inc.

reported an EBITDA of USD -20. 65 mn, indicating operational losses. Revenue generation is structured around a variety of business models that include direct sales and partnerships, although specific revenue figures are not disclosed. Looking ahead, Synthorx plans to launch new therapies that capitalize on their unique amino acid technology, with specific release dates to be announced as development progresses.

The company aims to expand its reach into European and Asian markets further by 2021. The recent IPO raised USD 131 mn, which will support these initiatives, including product development and market entry strategies.